Patent 12133923 was granted and assigned to RECODE THERAPEUTICS, INC. on November, 2024 by the United States Patent and Trademark Office.
Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.